Similarly, it has been described how liraglutide can improve the Dermatology Life Quality Index (DLQI) of diabetic patients with psoriasis and decrease the expression of IL-17, IL-23, and TNF-α, all pro-inflammatory cytokines involved in psoriasis and obesity pathogenesis [162,163]. Here, IL17A is linked to obesity due to melanocortin 4 receptor deficiency.